Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-induced immune dysfunction: the macrophage connection

K D Elgert1, D G Alleva, D W Mullins

  • 1Department of Biology, Virginia Polytechnic Institute and State University, Blacksburg 24061-0406, USA. kdelgert@vt.edu

Journal of Leukocyte Biology
|September 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses.

Scandinavian journal of immunology·2006
Same author

Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

Scandinavian journal of immunology·2006
Same author

A male genital tract-specific carbohydrate epitope on human CD52: implications for immunocontraception.

Tissue antigens·2002
Same author

Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

Clinical immunology (Orlando, Fla.)·2002
Same author

Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same journal

Correction to: IL-27 signaling negatively regulates FcɛRI-mediated mast cell activation and allergic response.

Journal of leukocyte biology·2026
Same journal

Autofluorescence enables detection and quantification of EETosis in human leukocyte cultures.

Journal of leukocyte biology·2026
Same journal

Cold Atmospheric Plasma as an Immunomodulator: Suppression of T-cell Hyperactivation and Graft-versus-Host Disease via Redox Regulation.

Journal of leukocyte biology·2026
Same journal

Distinct lymphocyte immune signatures to nivolumab and recombinant IL-7 ex vivo in patients with sepsis.

Journal of leukocyte biology·2026
Same journal

Eosinophil Essentials: Identification and Assessment of Activity.

Journal of leukocyte biology·2026
Same journal

Immune cell landscape reveals 5 immune-related subtypes and molecular characteristics with prognostic and therapeutic implications in pan-cancer.

Journal of leukocyte biology·2026
See all related articles

Cancer cells evade immune responses by manipulating macrophages (Mphis). Tumor-derived molecules reprogram Mphis to suppress antitumor immunity, hindering effective cancer treatment and immune response.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Macrophages (Mphis) play a dual role in immunity, capable of mediating tumor cytotoxicity and stimulating antitumor responses.
  • Cancer cells frequently evade immune surveillance, leading to immune dysfunction and compromised antitumor immunity.
  • Tumor growth is known to negatively impact macrophage function and phenotype, contributing to immune suppression.

Purpose of the Study:

  • To review evidence demonstrating how tumor-derived molecules redirect macrophage activities to promote tumor development.
  • To elucidate the mechanisms by which cancer exploits macrophages to create an immunosuppressive tumor microenvironment.
  • To discuss the controversial role of macrophages in tumor-induced immune suppression.

Main Methods:

Related Experiment Videos

  • Review of existing scientific literature and data.
  • Analysis of molecular mechanisms underlying macrophage reprogramming by tumor-derived factors.
  • Examination of the impact of specific cytokines, growth factors, and proteases on macrophage function.

    • Main Results:

    • Tumors produce various molecules (e.g., IL-4, IL-6, IL-10, TGF-beta1, M-CSF) that deactivate or suppress cytotoxic Mphi activity.
    • Tumor-derived molecules induce Mphi suppressor activity, contributing to immune evasion.
    • Differential regulation of Mphis in distinct tumor compartments suggests a complex, twofold immune suppression strategy.

    Conclusions:

    • Tumor-derived molecules are key mediators of immune suppression by reprogramming macrophages.
    • Understanding these molecular interactions is crucial for developing effective cancer immunotherapies.
    • Targeting Mphi-modulating tumor factors may restore antitumor immunity and improve patient outcomes.